An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer

A Non-interventional Study of Avastin in Combination With Paclitaxel for First Line Treatment in HER2 Negative Metastatic Breast Cancer

This prospective observational study will evaluate the use in clinical practice, efficacy and safety of Avastin (bevacizumab) in combination with paclitaxel in first line in patients with HER2-negative metastatic breast cancer. Data will be collected from eligible patients for up to 2.5 years.

Inclusion Criteria:

• Adult patients, >/= 18 years of age
• Locally recurrent or metastatic breast cancer
• No prior treatment for metastatic or locally recurrent disease
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2

Exclusion Criteria:

• History or clinical evidence of brain metastases
• Pregnancy
• Uncontrolled hypertension ( systolic > 150 mmHg and/or diastolic > 100 mmHg) or clinically significant (i.e. active) cardiovascular disease
• Major surgical procedure or significant traumatic injury within 28 days prior to enrolment